Louis Garguilo
ARTICLES BY LOUIS
-
6/19/2025
The art and science of late-stage/commercial formulation, compared to early-phase formulation, is a different ballgame, says Dileep Boinipally, currently utilizing CDMOs to advance a pipeline of oral and injectable candidates. He has a stadium full of advice for readers.
-
6/17/2025
Doug Bakan enjoys all the attention CDMOs give him nowadays at his biotech with GLP-1-related programs. But how is he selecting his external partners? Which are most trustworthy? Can he discern what they say is what they they're going to do? Here are his thoughts.
-
6/12/2025
Dileep Boinipally has extensive experience in formulation, manufacturing process development, and regulatory strategy. He’s adept at explaining all that, but Chief Editor Louis Garguilo got him to focus for readers on the ins-and-outs of the practice of early formulation development.
-
6/10/2025
Chief Editor Louis Garguilo analyzes a report projecting the biologics CDMO secondary packaging market could rise from $2.59 billion this year to USD $5.50 billion by 2034. Projecting so far into the future is tricky business, but Garguilo explains the ultimate value.
-
6/5/2025
"Be prepared. Structured. Work in a systematic fashion towards your CDMO selection." That's a rather non-psychedelic paraphrasing of Anthony Grenier, Reunion Neuroscience, a biotech pursuing the development of novel, synthetic psychedelic molecules. Here's more of his thoughts on CDMO selection.
-
6/3/2025
Outsourcing drug development and manufacturing is an attempt at purposeful action in a web of interdependent contingencies. The contingency top-of-mind today is President Trump’s tariff strategy, and global "negotiations" that have ushered in a supply-chain disquietude.
-
5/29/2025
CDMOs want GLP-1 projects. Doug Bakan of Kailera Therapeutics says, “We see companies growing their existing GLP-1 manufacturing capabilities or communicating plans to introduce them. Our job is to find out which in fact have capacity now, and the actual vision to continue to expand."
-
5/22/2025
Ali Pashazadeh is "a deep thinker" that our Chief Editor visits with annually. Recently, he asked Pashazadeh to help us think through the evolving policies of the new U.S. presidential administration and the tariff turbulence, as they relate to a biotech's development and manufacturing outsourcing.
-
5/20/2025
A Big Pharma professional is battling in the ring of outsourcing ideas, and she’s in the CDMO’s corner. Lynn Cinelli, VP Global Biologics Supply Chain, Bristol Myers Squibb, is fighting against sponsors who don’t recognize inefficiencies and flawed thinking fall hard on their external partners.
-
5/12/2025
“We hadn’t built a new site in the U.S. in more than 40 years until the first set of Trump tax cuts, so we need to see those either extended or improved to support this,” Eli Lilly CEO David Ricks recently said, announcing — in Washington, DC — plans to invest $27 billion to build four new manufacturing plants in the U.S.